EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Rationale and Design of the Randomized ‘Early Ventricular Assist Device’—Trial (VAD-DZHK3)

Christoph Knosalla iD, Gloria Färber iD, Andreas J Rieth iD, Rolf Wachter iD, Marius Placzek, Wolfgang Albert, Gerd Hasenfuß iD, Volkmar Falk iD, Tim Friede iD, VAD‐DZHK3 Investigators

ESC Heart Failure · 01.10.2025 · 12 (5) · 3731-3740

DOI: 10.1002/ehf2.15376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 20.07.2025. Verfasst von Christoph Knosalla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité, Berlin, Germany. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heart Failure, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: DZHK, Deutsches Zentrum für Herz-Kreislaufforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Bridge to transplantation (BTT) with durable, continuous-flow left ventricular assist devices (LVAD) of patients is a well-established treatment concept in patients awaiting heart transplantation (HTx). However, the role of elective LVAD implantation in patients with less advanced HF, but increased risk of decompensation remains uncertain. Methods and results The VAD-DZHK3 trial is an investigator-initiated, randomized controlled trial designed to assess whether an early strategy of elective LVAD implantation improves outcomes compared with a conventional approach involving optimal medical therapy and delayed device implantation only after clinical deterioration. Eligible patients are those with end-stage HF listed for cardiac transplantation. This is an event-driven study, that is, the study is completed once 120 events of the primary composite endpoint have been observed and all patients have at least 1 year of follow-up unless they died earlier. Patients meeting inclusion criteria who decline randomization are enrolled in a parallel observational registry reflecting standard care. The primary efficacy endpoint is survival free from high urgent cardiac transplantation, disabling stroke and HF hospitalizations (including emergency room HF visits >6 h).

Conclusions

The VAD-DZHK3 trial will provide guidance on the optimal timing and patient selection for LVAD implantation in heart transplant candidates, potentially redefining current standards of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesHeart FailureRandomized Controlled Trials as TopicHumansHeart TransplantationMaleFemaleTime FactorsFollow-Up StudiesWaiting Lists

Stichwörter der Autor:innen

Heart failureHeart transplantationLeft ventricular assist deviceMechanical circulatory support

Autor:innen und Institutionen

  • Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité, Berlin, Germany.
  • Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
  • Department of Thoracic and Cardiovascular Surgery Saarland, University Medical Center and Saarland University, Homburg, Germany.
  • Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich Schiller University of Jena, Jena, Germany.
  • Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

ORCID-Profile: Christoph Knosalla, Gloria Färber, Andreas J Rieth, Rolf Wachter, Gerd Hasenfuß, Volkmar Falk, Tim Friede

Förderung

  • DZHK
  • Deutsches Zentrum für Herz-Kreislaufforschung

Zitieren

APA

Knosalla, C., Färber, G., Rieth, A. J., Wachter, R., Placzek, M., Albert, W., Hasenfuß, G., Falk, V., Friede, T., & VAD‐DZHK3 Investigators (2025). Rationale and Design of the Randomized ‘Early Ventricular Assist Device’—Trial (VAD-DZHK3). ESC Heart Failure, 12(5), 3731-3740. https://doi.org/10.1002/ehf2.15376

Vancouver

Knosalla C, Färber G, Rieth AJ, Wachter R, Placzek M, Albert W, et al. Rationale and Design of the Randomized ‘Early Ventricular Assist Device’—Trial (VAD-DZHK3). ESC Heart Failure. 2025;12(5):3731-3740. doi:10.1002/ehf2.15376

BibTeX
@article{Knosalla2025,
  author = {Knosalla, Christoph and Färber, Gloria and Rieth, Andreas J and Wachter, Rolf and Placzek, Marius and Albert, Wolfgang and Hasenfuß, Gerd and Falk, Volkmar and Friede, Tim and VAD‐DZHK3 Investigators, VAD‐DZHK3 Investigators},
  title = {Rationale and Design of the Randomized ‘Early Ventricular Assist Device’—Trial (VAD-DZHK3)},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {5},
  pages = {3731--3740},
  doi = {10.1002/ehf2.15376}
}
Kostenlos starten →